Quarterly report pursuant to Section 13 or 15(d)

Note 3 - Revenue (Details Textual)

v3.24.1.1.u2
Note 3 - Revenue (Details Textual)
$ in Thousands
 1 Months Ended 3 Months Ended 12 Months Ended
Aug. 31, 2023
USD ($)
Jan. 31, 2023
USD ($)
Mar. 31, 2024
USD ($)
Jun. 30, 2023
USD ($)
Mar. 31, 2023
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2017
Sep. 30, 2023
USD ($)
May 19, 2021
USD ($)
Feb. 08, 2018
May 02, 2017
Increase in Contract With Customer Liability     $ 0                  
Decrease in Contract with Customer, Liability     $ 0   $ 1,700              
Amendment of the Second Seagen Amendment [Member]                        
Revenue from Contract with Customer, Excluding Assessed Tax           $ 10,100            
Genentech [Member]                        
Number Of Initial Research Programs                   2    
Contract with Customer, Liability, Revenue Recognized       $ 12,500                
Number Of Optional Additional Research Programs                   2    
B P Assets X I I Inc [Member] | Exclusive Product License Agreement [Member]                        
Contract with Customer, Milestone Payment Received $ 2,500                      
Seattle Genetics Inc. [Member] | License and Collaboration Agreement [Member]                        
Number of Research Programs                     3  
Seattle Genetics Inc. [Member] | Collaborative Arrangement [Member]                        
Revenue from Contract with Customer, Excluding Assessed Tax   $ 5,000         $ 5,000          
Astra Zeneca A B [Member] | License and Collaboration Agreement [Member]                        
Contract with Customer, Liability, Revenue Recognized       $ 4,000                
Contract with Customer, Liability, Current                 $ 3,500      
Astra Zeneca A B [Member] | License and Collaboration Agreement [Member] | Maximum [Member]                        
Number of Collaboration Products                       4
Astra Zeneca A B [Member] | License and Collaboration Agreement [Member] | Minimum [Member]                        
Number of Collaboration Products                       2
Les Laboratoires Servier And Institut De Recherches Internationales Servier [Member]                        
Number of Novel Proteins               1        
Les Laboratoires Servier And Institut De Recherches Internationales Servier [Member] | License and Collaboration Agreement [Member]                        
Contract with Customer, Liability, Current           $ 4,700            
Number of Programs               5        
License [Member] | Genentech [Member]                        
Contract with Customer, Liability, Total                   $ 20,000